IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) has appointed brain tumour research campaigner Dr Al Musella to its board as a non-executive director.
Musella brings almost three decades of experience as founder and president of the Musella Foundation for Brain Tumor Research and Information Inc, IQ-AI added.
Musella formed the first online support group for brain tumour patients in 1993, which has since evolved into the website, virtualtrials.org.
In addition, Musella has issued more than US$19.3 million in brain tumour research grants and co-payment assistance grants to help patients access treatments and has advocated FDA and Medicare approval for Optune, Temodar, Gliadel, Gleolan, Avastin and other drugs.
Trevor Brown, IQ-AI’s chief executive, said "Musella’s extensive network and experience will be invaluable as we forge ahead in the development of oral gallium maltolate and build upon our core imaging business".
As part of these board changes Vinod Kaushal will step down as non-executive director with immediate effect, said IQ-AI.